1. Home
  2. SELF vs GLTO Comparison

SELF vs GLTO Comparison

Compare SELF & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Self Storage Inc.

SELF

Global Self Storage Inc.

HOLD

Current Price

$5.03

Market Cap

57.8M

Sector

Real Estate

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$25.00

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SELF
GLTO
Founded
1983
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
54.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SELF
GLTO
Price
$5.03
$25.00
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$41.00
AVG Volume (30 Days)
43.8K
30.0K
Earning Date
11-07-2025
03-18-2026
Dividend Yield
5.77%
N/A
EPS Growth
N/A
N/A
EPS
0.16
N/A
Revenue
$12,733,279.00
N/A
Revenue This Year
$1.59
N/A
Revenue Next Year
$1.62
N/A
P/E Ratio
$31.38
N/A
Revenue Growth
3.36
N/A
52 Week Low
$4.73
$2.01
52 Week High
$5.89
$38.33

Technical Indicators

Market Signals
Indicator
SELF
GLTO
Relative Strength Index (RSI) 48.94 52.61
Support Level $4.90 $23.85
Resistance Level $5.15 $27.75
Average True Range (ATR) 0.08 2.77
MACD -0.00 0.01
Stochastic Oscillator 60.42 44.36

Price Performance

Historical Comparison
SELF
GLTO

About SELF Global Self Storage Inc.

Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: